Mavrilimumab
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Mavrilimumab
- DrugBank Accession Number
- DB12534
- Background
Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- CAM-3001
- Mavrilimumab
- External IDs
- CAM-3001
- CAM3001
- KPL-301
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Mavrilimumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Mavrilimumab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Mavrilimumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mavrilimumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Mavrilimumab. Amivantamab The risk or severity of adverse effects can be increased when Mavrilimumab is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Anifrolumab is combined with Mavrilimumab. Ansuvimab The risk or severity of adverse effects can be increased when Mavrilimumab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Mavrilimumab. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Mavrilimumab. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1158JD1P9A
- CAS number
- 1085337-57-0
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911343
- Wikipedia
- Mavrilimumab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Coronavirus Disease 2019 (COVID‑19) / Pneumonia 2 2 Completed Treatment Giant Cell Arteritis (GCA) 1 2 Completed Treatment Rheumatoid Arthritis 3 2 Not Yet Recruiting Treatment Acute Respiratory Failure / ARDS, Human / Coronavirus Disease 2019 (COVID‑19) / Viral Pneumonia 1 2 Not Yet Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 2 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / Pneumonia 1 2 Terminated Treatment Rheumatoid Arthritis 1 2, 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / COVID 1 1 Completed Treatment Healthy Subjects (HS) 1 1 Completed Treatment Rheumatoid Arthritis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on October 20, 2016 22:45 / Updated on August 13, 2021 04:44